Home / About US / Milestones _世界杯预选赛中国队赛程
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
2021-01

In January, the first patient was enrolled in Phase I clinical trial for MIL95 (CD47 antibody);

2021-04

In April, the first patient was enrolled in Phase I clinical trial for MIL93 (Claudin 18.2 antibody);

2021-05

In May, we filed IND application to NMPA for MIL97 (CD40 antibody), and we obtained IND approval from NMPA for MIL62 (Third-generation CD20 antibody) to treat PMN

2021-06

In June, the first patient was enrolled in Phase III clinical trial for MIL62 for the treatment of relapsed/refractory FL
We completed investments undertaken by, among others, Tigermed and WuXi Biologics.

2020-05

In May, we completed the Phase III trial for MIL60 (Bevacizumab biosimilar) and filed the NDA application in June;
we obtained IND approval from NMPA for MIL95 (CD47 antibody);

2020-07

In July, the first patient was enrolled in Phase I/IIa clinical trial for the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor;

2020-08

In August, the first patient was enrolled in Phase I clinical trial for MBS301 (HER2/HER2 bispecific antibody);

2020-10

In October, we obtained IND approval from NMPA for MIL93 (Claudin 18.2 antibody);

2020-12

In December, we obtained IND approval from NMPA for MIL62 to treat LN;
We completed investments undertaken by, among others, CICC Capital, CITIC Investment, LYZZ Capital, SDIC and Lake Bleu Capital.

2019-03

In March, we signed a collaboration agreement with InnoCare (stock code: 09969.HK) regarding the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor, and obtained IND approval from NMPA for the combination therapy in August;

2019-04

In April, we obtained IND approval from NMPA for MIL86 (PCSK9 antibody);

2019-09

In September, we filed a PCT patent application for MIL93 (Claudin 18.2 antibody);

2019-10

In October, we filed a PCT patent application for MIL97 (CD40 antibody);

2019-11

In November, the first patient was enrolled in Phase II clinical trial for MIL62 for the treatment of relapsed/refractory FL;
We completed investments undertaken by, among others, CASVC and E-Town International Investment.

2018-01

In January, we signed a collaboration agreement with Keymed (stock code: 02162.HK) regarding the development of MIL95 (CD47 antibody).

2017-03

In March, we signed a collaboration agreement with Betta (stock code: 300558.SZ) to develop, manufacture and commercialize MIL60 (Bevacizumab biosimilar), and the Phase III clinical trial for MIL60 was initiated in August;

2017-07

In July, we filed a PCT patent application for MBS301 (HER2/HER2 bispecific antibody);
In August, we filed a PCT patent application for MIL62 (Third-generation CD20 antibody).

2016-10

In October, we obtained IND approval from NMPA for our core product MIL62 (Third-generation CD20 antibody) for the treatment of relapsed/refractory B-cell lymphoma;
We completed investments undertaken by, among others, GIG and Harvest Investments.